MCRB - Earnings call transcript Q3 2020 | Seres Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Seres Therapeutics Third Quarter 2020 Earnings Conference Call. At this time all participants are in a listen mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions] Please be advice that this conference is being recorded. [Operator Instructions]. to conference like to now would hand over the Dr. I Investor Relations. Tanzi, Carlo Thank you. sir. go Please ahead,

Carlo Tanzi

and you, Thank morning. good

approval, of our the A.M. became press relating statements that the enrollment Our release at clinical to and update results may of found of studies, News you on of company's of to with quarter this and regulatory the X:XX and can available Investors be third XXXX remind differ and the be website. microbiome making forward-looking results equivalents any promise and financial a timing, operations. impact I'd our we potential therapeutics results Actual and to cash materially. Eastern will morning, fund Time our section & company's the cash the business like sufficiency

and these views of made obligation to are so. under Matt Any Officer. today's Chief the do to Risk for risks to Factors the which and SEC disclaim statements these by now the Eric Moltke uncertainties, I'll today's Shaff, Chief pass I'm of on President Henn, Chief Strategy future, call We On Eric. Medical joined subject call forward-looking the but will in any and as Dr. von filings. are we our today our recent Lisa only. discussed Terri Executive section also may available Chief Scientific Officer; update statements and statements call, Young, Officer Officer; Commercial Dr. Additionally, Q&A certain represent section.

Eric Shaff

families I you your safe good are and everyone. and healthy. morning, hope Carlo, Thanks, and

insights class and has pioneered Seres new translation to medicine. entire an past microbiome of of the decade Over the

Seres our the becoming the Based our market. design prevent first has oral company approval recent provided success, for we of study bacteria of microbiome transition landmark is on commercial changes we And specific consortium is believe to clinical SER-XXX, what treat therapeutic are and FDA disease. are therapeutics utility a to to microbiome proof believe functional the in our on era X an to been approach. definitive that capsule, become supports drug we that product organization. gut produce a This microbiome obtain Our in towards microbiome of Phase to bring and track

Our with drug the management serious is aspiration approach. to novel candidates with through SER-XXX microbiome and other our transform of disease therapeutic

of positive raise, fortify Our a marketplace, balance were support C. we SER-XXX reaffirmed statistically to expect exceeded be results, recurrent SER-XXX study required its threshold prior FDA far the the these our SER-XXX the significant X company. million from Since on promise of our Based the with success in difficile Phase the highlighted is substantial sheet $XXX ECOSPOR SER-XXX our results in able FDA the by strength capital has obtained results, we in equity adding new study that approximately to requirements patients infection. efficacy of we reaffirmed guidance III the and will the to single provided safety to result, submission. least study BLA regarding efficacy SER-XXX for to the efficacy enable basis The BLA filing. a III a FDA. provide also SER-XXX XXX for and its ECOSPOR filing. BLA SER-XXX database the guidance at as a The results patients the And this by study with

patients safety this in required our ongoing the remainder study we with our label that fulfill recurrent enroll SER-XXX end, to to open expect CDI, continue we in Towards and database. study of

Canada the making U.S. new clinical progress subjects and sites study. with study, across We are the into enrolling and the activating substantial

We product an have several SER-XXX initiated for activities key anticipated to prepare launch.

With significant analysis HCP naming efforts market reimbursement to XXXX and pricing scale manufacturing, our regards product in capabilities team. rapid manufacturing work, ahead and Keytruda Ege and was led payer our while Merck. at Officer. manufacturing scale, Seres an are leading are already we assessment Technology work. And will the education for company be efforts, John Chief to we education into as Dave launch including market We for research recently preparation We our commercial expanding of physicians including SER-XXX the in primary vital payers, have experience with with the of MSL his company succeeds Aunins, the the as SER-XXX. we potential plan and market. formed. product conducted important who joined Dave hired We look new commercialization uptake expected and successfully to from the Dave pharmaceuticals, since Seres of efforts deployment

company John will pleased very I'll that, call the the turn senior We advisor continue support Lisa. the over to that in are now capacity. With to

Lisa von Moltke

In were We Meeting. favorable treatment. American with well similar the results of presented extremely and recap as additional at CDI some X weeks end point at compared a a with placebo X Eric, I'll Phase highly study's also see SER-XXX recurrences to study post we to profile, The we October, reduction top good top our results the data as College begin looking results, a demonstrated data eight to week announced events clinical primary with of showing in late that SER-XXX absolute morning placebo. Gastroenterology Annual line Phase Thanks, remarkable eight- met pleased XX.X% of demonstrated the Scientific safety adverse August. a SER-XXX that that everyone. SER-XXX line

eight New rate was weeks was the endpoint. data XX recurrence primary the at post-administration, seen SER-XXX study's with the consistent of in the weeks, that at which results arm showed

administration we data by demonstrating in that similar SER-XXX stratified age Additionally, prior when the efficacy or by presented received. resulted antibiotic

enormous this many and that SER-XXX of expressed have advance enthusiasm have regarding burdens they interest disease, major could heard represent a for this medical field. have We physician highlighted the and substantial financial and SER-XXX

SER-XXX administered, colitis. patients SER-XXX comprised tract. is program, commensal from to which of ongoing healthy human isolated bacterial Phase moving ulcerative to our candidate moderate, in an study derived Now mild Xb clinically drug orally biologically the is gastrointestinal spores active an with

and a microbiome to believe We believe provide both intended monotherapy to combination is UC. as first-in-class of may microbiome microbiome SER-XXX a microbiome develop treat an therapeutic has associated the colitis. SER-XXX modulates a of treatment much potential with objective for also trigger a option ulcerative We that SER-XXX that reduce the needed to non-immunosuppressive and with Our the metabolites is a other approved inflammation. both dysfunctional agents. potentially impact as that SER-XXX in to used be amplifier and

XX in Now weeks to Xb short receive designed previous rate. showed course ulcerative used to active XXX preconditioning therapy. ECO-RESET C, lower Xb that is prior with colitis randomized of study was trial moderate was Arm remind dose. by who of patients patients the regimen highest the used same SER-XXX daily preconditioning vancomycin regimen that controlled arm patients A have three-arm you, received mild the placebo. A, a weeks enroll the by by In two induction of XXX the Phase a In patient's daily placebo B, to failed the Arm In of in weeks Arm a followed same of vancomycin that Arm eight received study remission clinical followed followed

XX% the reported, we This Phase studies COVID-XX on As Xb XXX target. has studies, based our on the now the is clinical previously pandemic trial. currently over enrolled including had study impact enrolling patient SER-XXX an

including a support implemented progress, has flexibility clinical providing trial strategies forward increased sites, at Our capture. to of additional number regarding aimed clinical maintaining team and mitigation data

trial patients comprising nivolumab an enroll therapy study Institute are study metastatic microbiome portfolio. and a and Parker an melanoma. checkpoint SER-XXX measured outcome. the of microbiome the we reflective ratio, candidate with SER-XXX checkpoint patients Cancer that, for With [ph], SER-XXX to associated as In is either orally safety, randomized two administered response to the drug MD immunotherapy. Cancer All SER-XXX oncology activity now tract, Phase randomized, in Xb placebo Now moving to Phase for inhibitor a efficacy and the inhibitor are derived and in receive anti-PD-X biomarkers I'll pass engraftment biologically SER-XX in with tolerability, of therapeutic FDA improvement targeting our is of outcome. bacteria of in collaboration evaluating signature and to response controlled increase placebo. the GI Center, With Matt. the Anderson with Xb continue or patient one its in an to clinical of at association immunotherapy with we our call SER-XXX approved bacteria and and The Immunotherapy,

Matthew Henn

Lisa, you, everyone. good and morning Thank

will and Phase evaluate related data, announce a evaluate next and pharmacokinetics modify to subjects dosing to and design in based that pathways is remission being includes and cohorts We linked study. are study The SER-XXX study. colitis. for human was reverse of are in Australia treatment safety and moderate SER-XXX the rationally assessments generation to In and epithelial bacterial the and to as the first endpoints. of approximately patients of consortia two pleased microbiome be and with microbial clinical cohort either measured the evaluate this metabolites and measures Zealand SER-XXX in SER-XXX ulcerative translation the assays to of designed efficacy very in microbiome in Xb modulate receive and clinical patient ulcerative being clinical that and Phase of tract placebo. to XX open from Xb -- human fermented Phase in-vivo the functional in integrity orally is patients is other SER-XXX engraftment. randomized to in in-vitro The cell incorporated as Xb gastrointestinal A from New the designed the XX cohort consortia a microbiome microbiome Seres using secondary first to PK SER-XXX ulcerative The microbe models. of dosed, of label was study bacterial disease evaluated designed, biomarkers for in in will and using subjects signatures platform SER-XXX The incorporate is efficacy subsequent barrier gastrointestinal mild objectives the incorporates our with conducted species total. learnings bacteria XX associated safety analysis has associated study colitis. by cohort drug inflammation second discovery strains candidate pre-clinical colitis. adults therapeutic and comprising with or

allergenic Moving gastrointestinal SER-XXX patients hematopoietic have microbiome SER-XXX bacteremia and due It built versus on rationally infection, receiving that immunology. our bacterial now designed disease in clinical cell to to orally designed, patients, stem and host and to candidate we infectious into transplantation. immunocompromised dosed, SER-XXX. disease development. advanced expertise fermented is graft in an prevent in including therapeutic mortality is

to that broadly. supported operational the stem financial outcomes antibiotic the We our provides more that novel cell technology CARB-X The will to support. and provide to and sepsis therapeutics program is bacterial resistant program grant and potential SER-XXX advance SER-XXX treat transplantation expect infections microbiome into for insights the by and improve bacterial prevent in clinical

pathogenic advances diversity important vegetative We in expect breadth Both of capabilities incorporated have cell human from can with Memorial represent cells XXXX which the our through the field tissues Cancer now impact in collaboration pipeline. Seres bacteria continued into in Phase Eric. knowledge bacteria Xb back and leading can turn these formulations. and and capabilities, tract and technology, underlying GMP the engage our in technologies to disease. we programs in to to advance manufacturing early our to the advance programs, continued Seres Center. mechanisms and study a both Through deliver drugs spore drug gastrointestinal these our lyophilize Further, Kettering be to call that the I'll biological program by that SER-XXX microbes SER-XXX and with into has Sloan programs refine

Eric Shaff

Matt. Thanks,

quarter $XX.X million for recent period of to Seres a net the XXXX, for XXXX. of as of same of overview financials. compared $XX.X loss our now million an reported Turning third to in loss the net a

net development and platform. ongoing the personnel and quarter expenses, company's of therapeutics was driven development clinical by third loss The expenses, primarily microbiome

compared million that securities the total Nestle million the end in in August with second In our with offering million later $XXX investments, in that can a in with the found financial regarding proceeds. in $XXX cash our of and to position, purchase of company as strong equity approximately net provided XX-Q quarter $XX.X today. quarter agreement Seres the information as a XXXX, and at intend completed third XXXX. equivalents the cash, financial public press file Additional ended be well release, we quarter approximately a

Nestle also milestone $XX that payment Seres our We a anticipate of X of million SER-XXX is receipt entitled Phase to associated part collaboration. as

our will to and against We our strength objectives. execute resources use top

recruit now been additional the microbiome and position. world company resources assets effective. has Our CMC our expand stage clinical therapeutics. the could available believe our [ph] new deepen our field therapeutics priorities utilize SER-XXX to to into of capabilities including our and to emerging to infrastructure, prepare augmenting be Seres We development further intend commercialization leading milestones, the long company category class for and where advance areas meaningful for to And pipeline existing extend we microbiome disease the to are leadership our R&D therapeutic talent

to lies Before call how excited in microbiome opening the I'd up ahead general. are reiterate space questions, Seres the for like we to your and by what

is Our highest completing the and first potential work BLA needed therapy. microbiome for ever the preparing launch for priority our of SER-XXX the

now ahead. of is an And to Our to a therapeutic time new operator, we who XXXX and working of thank to work that dedicated the exciting decade options up pioneering never want with lost the category, of goal in patients Seres. I for patients is advancing tirelessly With sight and a look creating many in this of open field new team, contributors. success culmination and for of our talented this need. questions. important This we'll medicine, in call treatment help of years forward the new

Operator

[Operator Ted Sandler. Tenthoff line from Piper Instructions] with Our first of a question comes

lines open. Your

Ted Tenthoff

you It's safety any to guidance Thank all where for on the And exciting. completed? when when Thank you you. that and you cohort. if with I much really enrollment maybe could a be on -- enrollment get Great. congrats sense so the maybe are additional for have progress. in want

Eric Shaff

and for morning, Good Ted, thanks question. the

then and maybe me Let to start some provide just ask I'll Lisa, color.

with we So, we that fairly the were did the prior that open Lisa, results the sites. at came open some color. ask, We're we recently. I label. But to to pleased reminder, And risk forward ready move to of we can that X a I August provide investments make we're number ensure label say started will progress. a Phase certainly, open I'm make as to the started extremely that to continuing continuing in maybe additional to --

Lisa von Moltke

Sure.

landscape [ph] a because making lot The trial getting there's with both fact first So of of results. of allows we're FMT that enthusiasm We're inclusion And for right fact headwinds also be making may vigilant that be said, the mindful is site this XXX might and in no But constrained. are a recurrent any for now, patients, COVID that placebo. us. Eric yes, the progress. as looking very cause we activation. progress new But this currently we're fact changing. that going of to that lot very we're good the The

Ted Tenthoff

you update. for the Thank That's helpful.

Eric Shaff

hard we're key for move operational to us, to up. finish a Just Obviously priority and working extremely forward. ourselves

Ted Tenthoff

for much so Thanks update. excellent. Great, the

Eric Shaff

question, Thanks for Ted. the

Operator

line And Joseph of with question Thome our & next in Company. the Cowen comes

line is Your open.

Joseph Thome

Hi, taking there. Thank and questions, you for my congrats progress. on the

is one first on XXX. The

include recurrence. if practice? did label indicate best does I you have where of sort XXX once that As that one of it's paradigm open more launched the And fit treatment first will What's study successfully in in the your patients can. guess then

and Or would programs? if to anticipate take you. see on candidate advancing forward? there other? is solid XXX, one data you Just do would both and time to the versus you want the look those Thank show XXX of for a both If data both, how forward at be they where taking you you

Eric Shaff

and don't the label, Yes, think to think thanks Why we for also opportunity. with XXX? comment the both. morning, about you're I Joe. asking it's on And I questions. but And two the start important maybe Good

study and asked open greater. they agreed. got mentioned, SER-XXX to FDA should We've the believe process. part as our for as first allow be course, us, will with set the BLA the of Lisa Certainly, patients part end the a patients Of into including to that of first label recurrence a recurrent which as broad of determined FDA, encourages we of we that the data including, negotiation applicable had be label

I helpful. perspective on But maybe come point So to just Lisa medical ask it to multiple can can the question. comment data we that that's first think versus as to then we relates second recurrence is the and the

Lisa von Moltke

Yes.

the microbiome So have that and further a indicative that. same recurrence are Once recur, the dysfunctional repair. they first for patients medical fact underpinnings it's needs essentially in the of that recurrence

FDA. So the be indication as But completely discussion will medically internally as the that label stated, our would KOLs appropriate. be see itself well a with as Eric we

Eric Shaff

which with move that just a So human technological leverage company microbiome I are a to we're human. maybe I'll the know, New can -- and in And, sets important is as achievement really forward. And really team, Matt important separate a we're recognize They're cannibalize your as second that step it's comment geographically first-in-class Xb data We other. about hugely to Zealand. Joe, with on that of the excited each studies. the Advantages But you first to we right. Maybe XXX, human and do we I ask in XXX the as right? to think look, really proud and defined help of. we're And sorts so approach. that say, as Australia, patient not think it's study a well datasets, patients XXX for significant course, learnings next there's from biologically strategy, think understanding XXX. think this in of rationale both incredibly XXX conducting as question dosing and the opportunity an really is in But best-in-class each for relates our I illustrative to to we XXX. for of there's the that two going really to

lot obviously, in be side, chain same the could XXX a our of a really which that that encouragement program could is more we with there's Xb dataset, efficient. a patients and On need. the XXX time, this at supply element, But had help

Matt programs gives applied ask that us of XXX just therapies the moving a in optimism the our design and some between effective of for I accrued were But leverage XXX lot and in XXX and achieving this on in of really remission how existing further to about I forward. patients misunderstanding terms can think successfully there's maybe are space. comment

Matthew Henn

sure. Yes,

the the are So, as design level then combining understand with these a and these a found in of species, our that human on from detail, human the generating guide can get as well we indicated, really And metabolites, using fine associated the insights human metabolites clinical from SER-XXX they're I impact, using in been the really well strains cell with into we've that pull research remission. And work those specifically And selection spite associated up and clinical different setting species SER-XXX disease are based particular both the trial And of have there various in design engine across those various are SER-XXX. real data how do because and the of strains microbe microbes these types clinical and combining that XXX are to these you from these direct subjects with engraft insights designing and the pathways. remission, look comes as that that power where of insights a well is what us drugs. themselves relevant various I of non the of assays, portfolio, as different our pathways, built give insights, able pieces in. with that we Seres our different together really that leveraging to associated think, clinical strength think information, metabolites instrumental helped at comes

Joseph Thome

Great. is very helpful. congrats Thanks That and again.

Eric Shaff

question, the Joe. for Thanks

Operator

John question Canaccord. the comes next Newman of line from Our with

open. line is Your

John Newman

very for And much question. morning. Good the my on Thanks congrats progress. guys. taking Hi,

you still might is give regarding to enrolling? sense data when SER-XXX. some whether is on some if completes that The I could had I SER-XXX. I us Second study it update was when And had as might us first you question enrolling. see we know question initial wondering

which interesting a in is study Phase you if in reason the things how Phase it's but interesting. because see. actually could of a asking curious, study? that quickly see I'm you study melanoma, into larger we is normally X the move are a don't got And It's design Just that control very -- arm, it's X, that

quickly curious there, to So how move study? you might as you just a larger do with something see if ahead interesting Thanks.

Eric Shaff

you morning thank the good John, for Yes, questions. and

we XXX. on on first the comment can to ask can Lisa might with I to comment. start me And Matt we ask XXX. then Let

we as So others the impacted course, for space. studies are the XXX, of in pandemic been have by conducting that

endoscopy require our part Of of course, protocol. clinical we as

the the early into spring, particularly constrained. So in part were we the summer, of pretty

reiterate for point enrollments, of and and that I'll seen the and and both said into been enrollment terms we the enroll fall, in of today, throughout signs screen continue there where the are have the today We year. were and the we've of beginning progress we not we encouragement summer at have to at

pandemic, relates than vaccine next. the is a give abilities implemented to our we have anything us goes your encouragement enroll Obviously, data it we related anybody no that encouraged moving came number that mitigation enrolling we ball this we where to the that hit out strategies of highly, are about patients Lisa, forward. continue morning. highly the as which in the But Obviously, the comments else's opportunity better forward the So before crystal excited going pandemic to with and XXX? that study. on

Lisa von Moltke

question No, will open, others as if and sites made the lot think always re-engage said, about stay even trial compensate anything. the various again, in But does Yes. influences. you you there's COVID for obviously, medical if system clinical of patients I whether a off the to space take with we as COVID for adjustments have that the

we're on keep spring. it. we're since we've an eye that liking the So, seen change going to the But

Eric Shaff

XXX. ask of And It's your the everybody to probably great. second then John, ground objectives Yes, the to important I on to maybe Maybe Matt comment can just question. in study.

turn for it a couple of to Matt, comments. me let So

Matthew Henn

sure. Yes,

insights nivolumab they therapy such comes learned SER-XXX. trial. as because as trial extreme this we've value size And clinical such, point are trials, with our exploratory. these evaluating safety, of placebo experience, very melanoma their placebo you is this And the tolerability even development a trials. trial earlier that metastatic important activity in from the the in running John, if the that as and patients And we smaller call, So certainly is plus out, SER-XXX combination through and have where gained designed we drug Lisa noted from controlled controlled in

to with SER-XXX, how in this subjects. our is really activity So understand is goal trial what its

at we might associated broader And be result look of engraftment in of this studies, with engraftment also a Xb look we Phase in SER-XXX. pending as is the and terms modality. a types to typically from the So Seres forward a as engraftment respect have in we'll of from will hard done what take the do we of but next at understand that biomarkers to as changes about path or trial is the And decisions our exploratory then this trial. with drug this learnings is look to what's results and at the do always data and make then the best microbiome

John Newman

you. Thank great. Okay,

Eric Shaff

Thank you, John.

Operator

Our next Oppenheimer. line comes from with the of Breidenbach Mark question

Your open. line is

Mark Breidenbach

Hey, really and quarter. one can one Maybe about I good the congrats about ask SER-XXX transformational on SER-XXX. morning and question

up First, satisfy is XX-week the to can patient I'm And the data FDA follow to also in study requirement expect for III ECOSPOR how see we from database wondering SER-XXX? the asking sometime early ECOSPOR much safety IV for XXXX? in

Eric Shaff

Yes.

disclosure will the to good we that are from the of Mark, the open schedule comment to data label to maybe I Thanks additional the the So, say study. plan will that further question. for data comment. we them for ask on of And to how present Lisa, continuing I'll well as Lisa FDA the study. clarify work as as morning. with part can

Lisa von Moltke

Sure.

XXX the XXX. you study, patients, the with the had recall XXX to that end of already regard will [ph] if to gotten safety So we with

to providing get started. So, waiting Eric and didn't we waste with with remainder regard we said, that discussing as while And discussions FDA Eric for any exactly for as we've been the that. schedule to what the time ahead noted, had were of XXX, those go also,

Now, internally the finished our study as this up with to math the based final soon. data summer. the be available do we on XX-week is Maybe when going OXX announcements XX-week very very, just

be to looking for community. to correct the like will we able that disseminate as information well all, medical would venues preserve obviously, And to the like So to and ability that. the we through to be get publications you as things to

venues. hard working those be we'll So to identify

Mark Breidenbach

you how Okay. would give for taking trials as you've if study And ECO-RESET us of respect questions. that and May pivotal size a would points? it. could Got know second [Technical serve registration could just a to terms sense SER-XXX, could from the colitis. potential for support differ of ECO-RESET with helpful I mentioned, in ulcerative previously be and two And Difficulty] thanks one

Operator

Instructions]. [Operator

from of Our Howerton comes next the with question Chris Jeffries.

line is Your open.

Chris Howerton

Hey, wanted there. try with a answer the previous I'm and question trail. moment? if the not waiting ECO-RESET sure with you to to fine I'm respect

Carlo Tanzi

us into difficulties technical of couple Folks we've It just having some Operator, Maybe look from looks sounds we're with Bear sounds things. like looks you guys. tight a can it the like that, could please. second. one folks. hold for lost

Operator

Yes.

Of line course. I do see Eric's is still connected.

Lisa von Moltke

can't he says, He hear anything.

Operator

Okay.

Just for moment.

Carlo Tanzi

X? Lisa, maybe the you can take Phase question Mark's

Lisa von Moltke

Yes.

results for the study. designing important next XXX will think incredibly I be

we will lot statistically a about sure think bigger trial effect we And a are an we size, or depend of on terms or size to that in similar see. the not whether think I need to make So trial significant.

like. results hear trial Are hard the to the you able to that you look of So really, without it's seeing speculate would next Hello. on were what okay? XXX, really

Chris Howerton

is Lisa. this I fine, heard know Howerton. don't don't guys I Chris you I just So, can if know, hear you me?

Lisa von Moltke

I can you. hear

Eric Shaff

We can some going you. hear you, There's can we can Chris. we But technical definitely on. issues hear Yes.

Chris Howerton

throw of happens. it I'll then Well, Alright. just good. see questions, couple very Maybe a awesome. out we'll and Okay,

the III which to said study, was I So XXX the one, for first Lisa, think ECOSPOR maybe had previously, study. the you what clarify just

safety I XXX patients comprise database? that the wanted had I that heard to just You confirm right. that number

Boston for the CMC the had seen expansion? second I specific was, area, plans facility the what in obviously, The think, are that question I beautiful I've there.

internally a augmented plans facility the that be those rationally augment would what in either obviously, and that? to see, design you like kind sourced or And entering would what to are terms the as to different expanding biologically capabilities more consortia, of support, to So, clinic more? of are the

Lisa von Moltke

Yes.

first the part of For the…

Eric Shaff

I'm line. Sorry. on back Guys,

time Lisa, the we Chris, first, we I on top the talk on line comment about Lisa But that can be results. Sorry, to first, there. comment the you the don't you at can XXX, was that why and just the lost announced second. clear

Lisa von Moltke

Yes. exactly No, it. that's

had it So the that extension. in in those well as was OXX, been as

in of the been OXX the exactly already had So start right. study. That's

Eric Shaff

Yep. here. And I line then think Chris, hangs and my phone hopefully on

let's -- to with right? we CMC, really We're have space we not a where these X think We are we have a moving patient seen are to step responsibility the SER-XXX. Phase take the help the hasn't serve look, results this to relates thrilled opportunity we here, we to really that now feel back As patients. only in phase for in significant innovation do a quite group And time. some so

we we some capacity, point to the interruption the sure availability right isn't drugs. an patients want with are ensure of serving there redundancy So in at that be to these that and

We dosing that house patient our as on are platform the synthetic scale. and these serve also the biologically XXX, we with of results, house, X only mentioned side of you patients opportunities well in progresses biological as the side first too. as think to both the But the at as there's the but our commercial and evidenced Phase currently not by on pipeline

the very manufacturing processes well pipeline. the the the drive we side bringing to perhaps stage looking later investments. chain, stage the fact on Dave be of earlier ensure to for supply not side forward, that that is board move for take as will also providing pipeline, as as seriously we're the illustrative of patients only both we think I the but we So, of And make

Chris Howerton

And appreciate thanks good. the questions. Okay. Very taking for Alright. I it.

Eric Shaff

Thanks for the question, Chris.

Operator

I'm any not And questions. Thank showing further you.

So now for to call management back over closing remark. turn I'll the

Eric Shaff

soon with attention you and look and to this good be a So Thanks forward you healthy hope week, morning. connecting again, well. that morning. thanks have great and your for we We

Operator

program. gentlemen, concludes the Ladies this and does

You have may day. and disconnect. you participating for now wonderful Thank a

Seres Therapeutics (MCRB) 9 Nov 202020 Q3 Earnings call transcript